Top of this page
Skip navigation, go straight to the content

Newsroom Press Releases

Transparency notifications BlackRock, Inc.

  • 2 Notifications referring to situation on 26 and 27 December 2018
  • Threshold crossed: 5%
  • Latest holding: 5,03 % 
Brussels (Belgium), 31 December 2018 – 20:00 (CET) – regulated information
 
1. Summary of the notifications
 
Pursuant to Article 14 of the law of 2 May 2007 on the disclosure of large shareholdings, UCB SA/NV announces that it has received 2 transparency notifications from BlackRock, Inc. (having its registered office at 55 East 52nd Street, New York, NY, 10055, U.S.A.), dated 27 and 28 December 2018 respectively.
 
In the first notification, BlackRock, Inc. has notified that, following a disposal of UCB shares with voting rights and of equivalent financial instruments by its affiliates, its total holding in UCB SA/NV has decreased and has crossed downwards the 5% threshold on 26 December 2018. 
 
In the second notification, BlackRock, Inc. has notified that, following an acquisition of UCB shares with voting rights and of equivalent financial instruments by its affiliates, its total holding in UCB SA/NV has increased and has crossed the 5% threshold on 27 December 2018.
 
On 26 December 2018, BlackRock, Inc. (taking into account the holding of its affiliates) owned 9 017 139 UCB shares with voting rights (versus 9 631 504 shares in its previous notification), representing 4.64% of the total number of shares issued by the company (194 505 658) (versus 4.95% in its previous notification), as well as 696 785 equivalent financial instruments (versus 712 409 in its previous notification) representing 0.36% of the total number of shares issued by the company (versus 0.37% in its previous notification). 
 
On 27 December 2018, BlackRock, Inc. (taking into account the holding of its affiliates) owned 9 072 842 UCB shares with voting rights, representing 4.66% of the total number of shares issued by the company, as well as 720 194 equivalent financial instruments, representing 0.37% of the total number of shares issued by the company.
 
2. Content of the notifications
 
2.1 The information mentioned hereafter was identical in both notifications:
  • Notification by: A parent undertaking or a controlling person.
  • Persons subject to the notification requirement
  • Threshold crossed (in %): 5%
  • Denominator: 194 505 658.
  • Chain of controlled undertakings through which the holding is effectively held:
Please see the full chain of control in the ‘Chain of Control’ tab.
 
2.2 The first transparency notification dated 27 December 2018 included the following specific information:
  • Reason for the notification: Acquisition or disposal of voting securities or voting rights. 
  • Date on which the threshold is crossed: 26 December 2018.
  • Notified details:

  • Additional information
The disclosure obligation arose due to total holdings for BlackRock, Inc. going below 5%.
 
2.3. The second transparency notification dated 28 December 2018 includes the following specific information:
  • Reason for the notification
Acquisition or disposal of voting securities or voting rights. 
Acquisition or disposal of financial instruments that are treated as voting securities.
  • Date on which the threshold is crossed: 27 December 2018.
  • Notified details:

  • Additional information
The disclosure obligation arose due to total holdings for BlackRock, Inc. going above 5%.
 
3. Further information 
 
This press release and the detailed transparency notifications are available on UCB SA/NV’s website via the following link.
An updated overview of the UCB SA/NV large shareholdings will be available on UCB SA/NV’s website via the following link.
 
Investor Relations
Antje Witte          
Investor Relations, UCB
T +32.2.559.94.14 antje.witte@ucb.com

Isabelle Ghellynck,
 Investor Relations, UCB
T+32.2.559.9588, isabelle.ghellynck@ucb.com 

About UCB
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 7 500 people in approximately 40 countries, the company generated revenue of € 4.5 billion in 2017. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB_news
 


Stay up-to-date on the latest news and information from UCB